As Nektar Therapeutics (NKTR) Stock Value Rose, Bridger Management LLC Trimmed by $12.87 Million Its Stake

February 23, 2018 - By Rodney Autry

Investors sentiment decreased to 1.4 in Q3 2017. Its down 0.49, from 1.89 in 2017Q2. It fall, as 15 investors sold NKTR shares while 52 reduced holdings. 26 funds opened positions while 68 raised stakes. 148.76 million shares or 1.09% more from 147.16 million shares in 2017Q2 were reported. First Republic Invest Mngmt has invested 0% in Nektar Therapeutics (NASDAQ:NKTR). Vanguard Grp Inc Inc holds 0.02% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 14.30 million shares. Ny State Teachers Retirement Systems holds 257,224 shares or 0.02% of its portfolio. 114,126 are owned by Texas Permanent School Fund. Stifel Fincl Corporation invested 0% in Nektar Therapeutics (NASDAQ:NKTR). 525,453 are held by Fmr Ltd Liability Corporation. Thrivent Fincl For Lutherans holds 0.01% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 95,730 shares. Deutsche Bank Ag invested in 0.02% or 1.27M shares. Susquehanna Intll Limited Liability Partnership owns 413,245 shares. Paradigm Asset Management Com owns 3,250 shares or 0.02% of their US portfolio. Nationwide Fund Advisors has invested 0.02% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Nj State Employees Deferred Compensation Plan invested in 20,000 shares or 0.09% of the stock. The Switzerland-based Credit Suisse Ag has invested 0.01% in Nektar Therapeutics (NASDAQ:NKTR). Brinker, a Pennsylvania-based fund reported 44,770 shares. 109,300 were accumulated by Endurant Cap Management L P.

Since September 6, 2017, it had 0 buys, and 18 sales for $25.90 million activity. Shares for $404,664 were sold by Nicholson John. Another trade for 2,426 shares valued at $201,212 was made by Doberstein Stephen K on Friday, February 16. Thomsen Jillian B. also sold $211,082 worth of Nektar Therapeutics (NASDAQ:NKTR) on Friday, February 16. Another trade for 83,333 shares valued at $1.79 million was made by ROBIN HOWARD W on Wednesday, September 6. Hora Maninder had sold 2,875 shares worth $238,453 on Friday, February 16. 3,477 shares were sold by Labrucherie Gil M, worth $288,382 on Friday, February 16.

Roberto Mignone decreased its stake in Nektar Therapeutics (NKTR) by 19.08% based on its latest 2017Q3 regulatory filing with the SEC. Bridger Management Llc sold 536,431 shares as the company’s stock rose 44.66% with the market. The hedge fund run by Roberto Mignone held 2.27 million shares of the major pharmaceuticals company at the end of 2017Q3, valued at $54.59 million, down from 2.81M at the end of the previous reported quarter. Bridger Management Llc who had been investing in Nektar Therapeutics for a number of months, seems to be less bullish one the $14.20B market cap company. The stock increased 0.39% or $0.34 during the last trading session, reaching $88.55. About 499,855 shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 41.52% since February 23, 2017 and is uptrending. It has outperformed by 24.82% the S&P500.

Bridger Management Llc, which manages about $3.11 billion and $1.67 billion US Long portfolio, upped its stake in Allergan Plc by 63,106 shares to 286,002 shares, valued at $58.62M in 2017Q3, according to the filing. It also increased its holding in Alexion Pharmaceuticals Inc (NASDAQ:ALXN) by 349,114 shares in the quarter, for a total of 555,120 shares, and has risen its stake in Mgm Resorts International (NYSE:MGM).

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on March, 7. They expect $-0.35 EPS, down 25.00 % or $0.07 from last year’s $-0.28 per share. After $0.37 actual EPS reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts -194.59 % negative EPS growth.

More notable recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: which released: “Nektar Therapeutics: What The Bristol-Myers Squibb Deal For NKTR-214 Entails” on February 15, 2018, also with their article: “Nektar Gets a Payday But No Mega-Buyout” published on February 14, 2018, published: “Nektar Therapeutics Weighs Options Including Sale” on February 02, 2018. More interesting news about Nektar Therapeutics (NASDAQ:NKTR) were released by: and their article: “Free Research Reports on These Biotech Stocks — Navidea Biopharma, Nektar …” published on February 16, 2018 as well as‘s news article titled: “Here’s What Was Behind Nektar Therapeutics Stupendous 40% Jump in January” with publication date: February 07, 2018.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

Among 9 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics had 21 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given on Monday, September 21 by Roth Capital. On Tuesday, July 18 the stock rating was maintained by J.P. Morgan with “Buy”. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given on Tuesday, May 30 by Roth Capital. Aegis Capital maintained Nektar Therapeutics (NASDAQ:NKTR) rating on Monday, June 5. Aegis Capital has “Buy” rating and $2700 target. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given on Wednesday, August 30 by Roth Capital. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Aegis Capital on Tuesday, November 8. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given on Wednesday, August 16 by Jefferies. As per Wednesday, August 9, the company rating was maintained by Roth Capital. The rating was initiated by Canaccord Genuity on Thursday, November 9 with “Buy”. The firm earned “Hold” rating on Wednesday, August 26 by TheStreet.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.